Thomas E Witzig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4414210/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <scp>FUSION NHL</scp> 001 trial. Cancer Reports, 2023, 6, .	1.4	6
2	Prospective evaluation of highâ€dose methotrexate pharmacokinetics in adult patients with lymphoma usingÂnovel determinants of kidney function. Clinical and Translational Science, 2022, 15, 105-117.	3.1	7
3	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	5.2	9
4	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
5	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	6.2	7
6	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
7	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
8	Real World Long-term Follow-up Experience with Yttrium-90Âibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 618-625.	0.4	4
9	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e815-e825.	0.4	2
10	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	6.2	1
11	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	2.9	0
12	Methylated DNA markers in early detection of lymphoma: Discovery, validation, and clinical pilot Journal of Clinical Oncology, 2022, 40, 7562-7562.	1.6	0
13	Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with <i>TET2-</i> mutant clonal cytopenias of undetermined significance Journal of Clinical Oncology, 2022, 40, TPS7076-TPS7076.	1.6	1
14	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis Journal of Clinical Oncology, 2022, 40, e19562-e19562.	1.6	0
15	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances, 2022, 6, 5210-5221.	5.2	2
16	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
17	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood, 2021, 137, 513-523.	1.4	9
18	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leukemia and Lymphoma, 2021, 62, 247-251.	1.3	8

#	Article	IF	CITATIONS
19	Testicular <scp>FDGâ€PET</scp> / <scp>CT</scp> uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	4.1	3
20	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
21	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	6.2	9
22	Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. Blood Advances, 2021, 5, 1194-1198.	5.2	14
23	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Supportive Care in Cancer, 2021, 29, 5293-5301.	2.2	10
24	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer Journal, 2021, 11, 65.	6.2	3
25	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. Blood Cancer Journal, 2021, 11, 56.	6.2	3
26	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica, 2021, 106, 2261-2264.	3.5	0
27	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 2021, 39, 1329-1338.	1.6	60
28	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Scientific Reports, 2021, 11, 8318.	3.3	3
29	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 1317-1328.	1.6	132
30	Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 423-430.	2.4	10
31	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy Journal of Clinical Oncology, 2021, 39, 8049-8049.	1.6	1
32	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma Journal of Clinical Oncology, 2021, 39, e19501-e19501.	1.6	0
33	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type Journal of Clinical Oncology, 2021, 39, e19547-e19547.	1.6	2
34	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis Journal of Clinical Oncology, 2021, 39, 7542-7542.	1.6	1
35	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology, 2021, 39, e13569-e13569.	1.6	1
36	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma Journal of Clinical Oncology, 2021, 39, 7522-7522.	1.6	3

#	Article	IF	CITATIONS
37	Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	1.6	16
38	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	12.8	44
39	Outcomes in mantle cell lymphoma with central nervous system involvement Journal of Clinical Oncology, 2021, 39, e19527-e19527.	1.6	4
40	Diffuse large B-cell lymphoma with leukemic involvement Journal of Clinical Oncology, 2021, 39, e19552-e19552.	1.6	0
41	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	4.1	5
42	Clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma Journal of Clinical Oncology, 2021, 39, 2500-2500.	1.6	3
43	Assessment of fixedâ€duration therapies for treatmentâ€naÃ⁻ve <scp>Waldenström</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
44	MCIR1: A patientâ€derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. European Journal of Haematology, 2021, 107, 458-465.	2.2	1
45	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	6.2	4
46	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27
47	Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma. Oncologist, 2021, 26, e2079-e2081.	3.7	2
48	Outcomes in primary cutaneous diffuse large B ell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	1.7	8
49	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
50	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncology Practice, 2021, 17, e1382-e1393.	2.9	5
51	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	6.2	3
52	A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy. Shock, 2021, 55, 700-716.	2.1	31
53	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. Blood, 2021, 138, 1415-1415.	1.4	1
54	Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2021, 138, 621-621.	1.4	2

#	Article	IF	CITATIONS
55	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ ² -NIS). Blood, 2021, 138, 1333-1333.	1.4	Ο
56	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	1.4	1
57	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. Blood, 2021, 138, 3523-3523.	1.4	0
58	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	1.4	2
59	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood, 2021, 138, 2429-2429.	1.4	1
60	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	1.4	0
61	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. Blood, 2021, 138, 2524-2524.	1.4	1
62	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	1.4	0
63	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1439-1439.	1.4	Ο
64	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. Blood, 2021, 138, 2527-2527.	1.4	3
65	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. Haematologica, 2020, 105, e72-e75.	3.5	11
66	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. Leukemia and Lymphoma, 2020, 61, 318-327.	1.3	9
67	lbrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
68	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
69	Addition of venetoclax at time of progression in ibrutinibâ€ŧreated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American Journal of Hematology, 2020, 95, E57-E60.	4.1	9
70	Myc matters in HIV-associated lymphoma. Blood, 2020, 136, 1217-1218.	1.4	2
71	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist, 2020, 25, 974-980.	3.7	15
72	Bone involvement on PET/CT predicts eventâ€free survival in follicular lymphoma Grade 3B. British Journal of Haematology, 2020, 191, e41-e43.	2.5	2

#	Article	IF	CITATIONS
73	Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. Redox Biology, 2020, 36, 101657.	9.0	12
74	Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. Leukemia and Lymphoma, 2020, 61, 2274-2276.	1.3	4
75	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematology,the, 2020, 7, e490-e497.	4.6	14
76	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research, 2020, 26, 4468-4477.	7.0	16
77	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist, 2020, 25, 689-695.	3.7	7
78	Magnesium: The overlooked electrolyte in blood cancers?. Blood Reviews, 2020, 44, 100676.	5.7	18
79	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. Blood, 2020, 136, 39-40.	1.4	3
80	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
81	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	1.4	2
82	What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?. Hematology/Oncology Clinics of North America, 2020, 34, 825-835.	2.2	2
83	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. Blood, 2020, 136, 34-35.	1.4	0
84	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood, 2020, 136, 3-4.	1.4	1
85	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-21.	1.4	0
86	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. Blood, 2020, 136, 17-18.	1.4	0
87	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	1.4	0
88	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	1.4	0
89	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	1.4	0
90	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Blood, 2020, 136, 47-48.	1.4	0

#	Article	IF	CITATIONS
91	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
92	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
93	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	1.4	26
94	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
95	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2019, 37, 1819-1827.	1.6	44
96	Impact of metformin use on the outcomes of newly diagnosed diffuse large B ell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	2.5	12
97	Work-Life Balance Solutions for Physicians—It's All About You, Your Work, and Others. Mayo Clinic Proceedings, 2019, 94, 573-576.	3.0	9
98	Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood, 2019, 134, 363-373.	1.4	37
99	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 48.	6.2	24
100	Detection of extranodal and spleen involvement by FDGâ€₽ET imaging predicts adverse survival in untreated follicular lymphoma. American Journal of Hematology, 2019, 94, 786-793.	4.1	15
101	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia and Lymphoma, 2019, 60, 2712-2719.	1.3	42
102	Host genetic variation in tumor necrosis factor and nuclear factorâ€ÎºB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American Journal of Hematology, 2019, 94, E153-E155.	4.1	1
103	Acalabrutinib for mantle cell lymphoma. Blood, 2019, 133, 2570-2574.	1.4	19
104	The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. Blood Cancer Journal, 2019, 9, 24.	6.2	7
105	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	5.2	15
106	Primary Cutaneous Acral CD8+ T-Cell Lymphoma—A Single Center Review of 3 Cases and Recent Literature Review. American Journal of Dermatopathology, 2019, 41, 644-648.	0.6	7
107	Acute coronary syndromes in patients with active hematologic malignancies $\hat{a} \in \hat{a}$ Incidence, management, and outcomes. International Journal of Cardiology, 2019, 275, 6-12.	1.7	27
108	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28

#	Article	IF	CITATIONS
109	Role of systemic highâ€dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990â€2018. American Journal of Hematology, 2019, 94, 291-298.	4.1	40
110	Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. Journal of Clinical Investigation, 2019, 129, 1612-1625.	8.2	64
111	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. Blood, 2019, 134, 4092-4092.	1.4	4
112	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2019, 134, 4306-4306.	1.4	3
113	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. Blood, 2019, 134, 1610-1610.	1.4	3
114	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2019, 134, 467-467.	1.4	29
115	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
116	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2019, 134, 468-468.	1.4	8
117	Minimal Residual Disease (MRD) Assessment in the ECOC1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). Blood, 2019, 134, 751-751.	1.4	18
118	Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. Blood, 2019, 134, 2809-2809.	1.4	4
119	Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values. Blood, 2019, 134, 2811-2811.	1.4	1
120	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study Journal of Clinical Oncology, 2019, 37, 7559-7559.	1.6	8
121	Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. Blood, 2019, 134, 1544-1544.	1.4	2
122	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
123	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HROoL) Analysis of the International Robust Study, Blood, 2019, 134, 3475-3475.	1.4	0
124	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. Blood, 2019, 134, 1480-1480.	1.4	0
125	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2981-2981.	1.4	0
126	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	1.4	0

#	Article	IF	CITATIONS
127	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. Blood, 2019, 134, 4101-4101.	1.4	0
128	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. Blood, 2019, 134, 5293-5293.	1.4	2
129	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
130	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2128-2134.	1.3	5
131	Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1947-1953.	4.4	50
132	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer Journal, 2018, 8, 27.	6.2	10
133	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
134	Eventâ€free survival at 24Âmonths captures central nervous system relapse of systemic diffuse large Bâ€cell lymphoma in the immunochemotherapy era. British Journal of Haematology, 2018, 183, 149-152.	2.5	5
135	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica, 2018, 103, 297-303.	3.5	17
136	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. Journal of Clinical Oncology, 2018, 36, 1603-1610.	1.6	93
137	A new tool in the cancer immunotherapy toolbox?. Annals of Lymphoma, 2018, 1, 1-1.	4.5	1
138	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer Journal, 2018, 8, 110.	6.2	22
139	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. Nutrition and Cancer, 2018, 70, 1088-1090.	2.0	4
140	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
141	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	4.1	16
142	Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell, 2018, 34, 700-706.	16.8	154
143	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer Journal, 2018, 8, 63.	6.2	22
144	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	6.2	26

#	Article	IF	CITATIONS
145	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
146	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
147	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. British Journal of Haematology, 2018, 183, 196-211.	2.5	16
148	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. Haematologica, 2018, 103, 1899-1907.	3.5	52
149	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 664-672.e2.	0.4	6
150	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2018, 132, 454-454.	1.4	1
151	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study. Blood, 2018, 132, 1615-1615.	1.4	1
152	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. Blood, 2018, 132, 4204-4204.	1.4	1
153	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2018, 132, 2937-2937.	1.4	2
154	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	1.4	1
155	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials. Blood, 2018, 132, 2962-2962.	1.4	1
156	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
157	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4139-4139.	1.4	0
158	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
159	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. Blood, 2018, 132, 5401-5401.	1.4	1
160	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
161	Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. Blood, 2018, 132, 574-574.	1.4	0
162	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0

#	Article	IF	CITATIONS
163	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
164	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	1.4	0
165	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
166	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. Blood, 2018, 132, 4140-4140.	1.4	0
167	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LRâ€CD) for untreated lowâ€grade nonâ€Hodgkin lymphoma requiring therapy. American Journal of Hematology, 2017, 92, 467-472.	4.1	15
168	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. American Journal of Hematology, 2017, 92, 448-453.	4.1	26
169	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Laboratory Investigation, 2017, 97, 494-497.	3.7	24
170	Risk of histological transformation and therapyâ€related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. British Journal of Haematology, 2017, 178, 427-433.	2.5	15
171	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). American Journal of Hematology, 2017, 92, 1004-1010.	4.1	7
172	Associations between elevated preâ€treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. American Journal of Hematology, 2017, 92, 752-758.	4.1	23
173	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4127-4137.	7.0	135
174	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma $\hat{a} \in $ tissue remains the issue. Leukemia and Lymphoma, 2017, 58, 2342-2348.	1.3	10
175	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
176	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology, 2017, 46, 1753-1754i.	1.9	57
177	Longâ€ŧerm analysis of phase II studies of singleâ€agent lenalidomide in relapsed/refractory mantle cell lymphoma. American Journal of Hematology, 2017, 92, E575-E583.	4.1	17
178	Pseudo-monoclonal gammopathy: a report of four cases. Haematologica, 2017, 102, e466-e469.	3.5	11
179	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ⁻ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
180	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	27.0	3,865

#	Article	IF	CITATIONS
181	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	2.7	15
182	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology, 2016, 12, 1553-1563.	2.4	85
183	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	4.1	41
184	Reduction in Câ€reactive protein indicates successful targeting of the ILâ€1/ILâ€6 axis resulting in improved survival in early stage multiple myeloma. American Journal of Hematology, 2016, 91, 571-574.	4.1	75
185	Asthma and orbital immunoglobulin G4–related disease. Annals of Allergy, Asthma and Immunology, 2016, 116, 313-316.	1.0	13
186	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica, 2016, 101, 1237-1243.	3.5	42
187	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180
188	Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085) Tj ETQqQ e309-e316.	0 0 rgBT 4.6	/Overlock 10 50
189	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	1.4	1
190	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	1.4	1
191	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". Blood, 2016, 128, 1750-1750.	1.4	2
192	Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance. Blood, 2016, 128, 2761-2761.	1.4	1
193	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
194	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
195	Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells. Blood, 2016, 128, 3018-3018.	1.4	5
196	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	1.4	2
197	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	1.4	5
198	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	1.4	5

#	Article	IF	CITATIONS
199	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). Blood, 2016, 128, 4392-4392.	1.4	8
200	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. Blood, 2016, 128, 5299-5299.	1.4	1
201	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST) Journal of Clinical Oncology, 2016, 34, 7538-7538.	1.6	2
202	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. Blood, 2016, 128, 3036-3036.	1.4	0
203	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
204	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	1.4	0
205	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. Blood, 2016, 128, 107-107.	1.4	0
206	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0
207	Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. Blood, 2016, 128, 4103-4103.	1.4	1
208	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood, 2015, 125, 992-998.	1.4	47
209	A phase <scp>II</scp> trial of <scp>RCHOP</scp> followed by radioimmunotherapy for early stage (stages I/ <scp>II</scp>) diffuse large Bâ€cell nonâ€Hodgkin lymphoma: <scp>ECOG</scp> 3402. British Journal of Haematology, 2015, 170, 679-686.	2.5	19
210	Longerâ€ŧerm followâ€up and outcome by tumour cell proliferation rate (Kiâ€67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCLâ€001(EMERGE) pivotal trial. British Journal of Haematology, 2015, 170, 496-503.	2.5	34
211	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
212	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood, 2015, 126, 328-335.	1.4	92
213	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AÂSingle-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 699-704.	0.4	11
214	The Effect of a Neutropenic Diet on Infection and Mortality Rates in Cancer Patients: A Meta-Analysis. Nutrition and Cancer, 2015, 67, 1232-1240.	2.0	40
215	Response to: â€~ls rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamotoet al. Annals of the Rheumatic Diseases, 2015, 74, e47-e47.	0.9	3
216	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. Journal of Clinical Oncology, 2015, 33, 251-257.	1.6	319

#	Article	IF	CITATIONS
217	Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma. Blood, 2015, 126, 1557-1557.	1.4	2
218	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	1.4	6
219	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	1.4	8
220	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 3992-3992.	1.4	1
221	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). Blood, 2015, 126, 813-813.	1.4	1
222	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). Blood, 2015, 126, 834-834.	1.4	17
223	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma Journal of Clinical Oncology, 2015, 33, TPS8600-TPS8600.	1.6	1
224	Translation initiation complex elF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget, 2015, 6, 9488-9501.	1.8	42
225	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	1.4	0
226	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. Blood, 2015, 126, 703-703.	1.4	4
227	Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 3947-3947.	1.4	0
228	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	1.4	0
229	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	1.4	0
230	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	1.4	0
231	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 1456-1456.	1.4	0
232	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B―and Tâ€cell nonâ€ <scp>H</scp> odgkin lymphoma. American Journal of Hematology, 2014, 89, 1116-1120.	4.1	16
233	Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2014, 55, 2728-2738.	1.3	44
234	Longâ€ŧerm results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology, 2014, 89, 237-242.	4.1	68

#	Article	IF	CITATIONS
235	Elevated serum monoclonal and polyclonal free light chains and interferon inducible proteinâ€10 predicts inferior prognosis in untreated diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2014, 89, 417-422.	4.1	18
236	Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab. Case Reports in Hematology, 2014, 2014, 1-4.	0.4	3
237	The utility of restaging bone marrow biopsy in PETâ€negative patients with diffuse large Bâ€cell lymphoma and baseline bone marrow involvement. American Journal of Hematology, 2014, 89, 865-867.	4.1	9
238	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
239	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
240	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2014, 32, 1066-1073.	1.6	304
241	Origins research in large cell lymphoma—time for action?. Lancet Oncology, The, 2014, 15, 674-675.	10.7	3
242	Elevated soluble <scp>IL</scp> â€2 <scp>R</scp> α, <scp>IL</scp> â€8, and <scp>MIP</scp> â€1β levels are associated with inferior outcome and are independent of <scp>MIPI</scp> score in patients with mantle cell lymphoma. American Journal of Hematology, 2014, 89, E223-7.	4.1	36
243	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. Blood, 2014, 124, 628-628.	1.4	18
244	Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. American Journal of Hematology, 2013, 88, 152-154.	4.1	56
245	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology, 2013, 31, 3272-3278.	1.6	259
246	The use of ⁹⁰ yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?. Leukemia and Lymphoma, 2013, 54, 2586-2587.	1.3	0
247	Moving Radioimmunotherapy Forward for Follicular Lymphoma. Journal of Clinical Oncology, 2013, 31, 294-296.	1.6	3
248	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰ yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed Bâ€cell nonâ€Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 589-593.	4.1	33
249	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. Journal of Clinical Oncology, 2013, 31, 3688-3695.	1.6	320
250	A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling. PLoS ONE, 2013, 8, e67851.	2.5	20
251	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. Blood, 2013, 122, 3057-3057.	1.4	2
252	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	1.4	2

#	Article	IF	CITATIONS
253	Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells. Blood, 2013, 122, 636-636.	1.4	5
254	A Novel Long Non-Coding RNA, SNHG4 Complex With Eukaryotic Initiation Factor-4E and Regulate Aberrant Protein Translation In Mantle Cell Lymphoma: Implications For Novel Biomarker. Blood, 2013, 122, 81-81.	1.4	6
255	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. Blood, 2013, 122, 844-844.	1.4	5
256	SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark. Blood, 2013, 122, 632-632.	1.4	1
257	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	1.4	0
258	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
259	An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab. Blood, 2013, 122, 1641-1641.	1.4	Ο
260	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. Blood, 2013, 122, 4288-4288.	1.4	0
261	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	1.4	Ο
262	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	1.4	0
263	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4306-4306.	1.4	0
264	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica, 2012, 97, 262-269.	3.5	175
265	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood, 2012, 119, 476-487.	1.4	91
266	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood, 2012, 120, 4400-4406.	1.4	53
267	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1799-1806.	2.5	22
268	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. Cytokine, 2012, 60, 882-889.	3.2	50
269	Elevated pretreatment serum levels of interferonâ€inducible proteinâ€10 (CXCL10) predict disease relapse and prognosis in diffuse large Bâ€cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869.	4.1	37
270	Hematologist/oncologist diseaseâ€specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer, 2012, 118, 1827-1837.	4.1	38

#	Article	IF	CITATIONS
271	Sorafenib, a multikinase inhibitor, is effective in vitro against nonâ€hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. American Journal of Hematology, 2012, 87, 277-283.	4.1	26
272	IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. Journal of Clinical Investigation, 2012, 122, 1271-1282.	8.2	243
273	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. Blood, 2012, 120, 1540-1540.	1.4	2
274	CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial. Blood, 2012, 120, 1638-1638.	1.4	20
275	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	1.4	2
276	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402) Blood, 2012, 120, 2687-2687.	1.4	2
277	Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma. Blood, 2012, 120, 3661-3661.	1.4	1
278	Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results. Blood, 2012, 120, 3680-3680.	1.4	2
279	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. Blood, 2012, 120, 689-689.	1.4	8
280	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis Blood, 2012, 120, 946-946.	1.4	1
281	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia Journal of Clinical Oncology, 2012, 30, 8043-8043.	1.6	Ο
282	LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL Journal of Clinical Oncology, 2012, 30, 8053-8053.	1.6	0
283	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology, 2012, 30, TPS8118-TPS8118.	1.6	1
284	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0
285	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood, 2012, 120, 1525-1525.	1.4	Ο
286	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (â^') Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	1.4	1
287	Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial. Blood, 2012, 120, 1792-1792.	1.4	0
288	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	1.4	0

#	Article	IF	CITATIONS
289	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. Blood, 2012, 120, 1575-1575.	1.4	0
290	A Novel STAT3 mutation Associated with Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling Blood, 2012, 120, 2690-2690.	1.4	1
291	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL Blood, 2012, 120, 2741-2741.	1.4	0
292	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0
293	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	1.4	0
294	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL) Blood, 2012, 120, 2634-2634.	1.4	0
295	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes Blood, 2012, 120, 2655-2655.	1.4	0
296	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leukemia and Lymphoma, 2011, 52, 1188-1199.	1.3	33
297	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood, 2011, 118, 4053-4061.	1.4	136
298	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncology, The, 2011, 12, 361-368.	10.7	151
299	Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood, 2011, 118, 2809-2820.	1.4	116
300	lmmunosuppressive CD14+HLA-DRlow/â^' monocytes in B-cell non-Hodgkin lymphoma. Blood, 2011, 117, 872-881.	1.4	218
301	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, 2011, 117, 1492-1498.	1.4	110
302	Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1. Blood, 2011, 117, e190-e197.	1.4	40
303	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood, 2011, 118, 5540-5549.	1.4	72
304	The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed nonâ€Hodgkin lymphoma of distinct histological origin. British Journal of Haematology, 2011, 154, 477-481.	2.5	42
305	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	4.1	57
306	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology, 2011, 86, 998-1000.	4.1	28

#	Article	IF	CITATIONS
307	Higher response to lenalidomide in relapsed/refractory diffuse large Bâ€cell lymphoma in nongerminal center Bâ€cell–like than in germinal center Bâ€cell–like phenotype. Cancer, 2011, 117, 5058-5066.	4.1	277
308	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2011, 29, 1620-1626.	1.6	70
309	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience. Blood, 2011, 118, 1580-1580.	1.4	1
310	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. Blood, 2011, 118, 1640-1640.	1.4	1
311	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). Blood, 2011, 118, 1790-1790.	1.4	1
312	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2011, 118, 2656-2656.	1.4	26
313	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	1.4	1
314	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. Blood, 2011, 118, 2945-2945.	1.4	1
315	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. Blood, 2011, 118, 1570-1570.	1.4	15
316	TGF-β Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 1586-1586.	1.4	1
317	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	1.4	1
318	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 770-770.	1.4	0
319	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	1.4	0
320	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	1.4	0
321	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	1.4	0
322	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	1.4	0
323	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. Blood, 2011, 118, 3642-3642.	1.4	0
324	Phase I, Multicenter, Open Label, Dose Escalation of 90yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma. Blood, 2011, 118, 1648-1648.	1.4	0

#	Article	IF	CITATIONS
325	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	1.4	1
326	Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of Cpg Islands,. Blood, 2011, 118, 3678-3678.	1.4	0
327	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	1.4	0
328	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 95-113.	0.4	37
329	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer, 2010, 116, 2201-2207.	4.1	89
330	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology, 2010, 85, 320-324.	4.1	197
331	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1408-1414.	1.6	132
332	Signal Transduction Inhibitor Therapy for Lymphoma. Hematology American Society of Hematology Education Program, 2010, 2010, 265-270.	2.5	42
333	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 4191-4198.	1.6	184
334	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clinic Proceedings, 2010, 85, 824-833.	3.0	152
335	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma Blood, 2010, 116, 2802-2802.	1.4	2
336	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	1.4	5
337	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	1.4	1
338	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. Blood, 2010, 116, 4168-4168.	1.4	5
339	OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy. Blood, 2010, 116, 970-970.	1.4	1
340	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	1.4	2
341	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	1.4	0
342	Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites. Blood, 2010, 116, 4160-4160.	1.4	0

#	Article	IF	CITATIONS
343	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	1.4	1
344	Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2408-2408.	1.4	0
345	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2409-2409.	1.4	0
346	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. Blood, 2010, 116, 140-140.	1.4	10
347	GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment. Blood, 2010, 116, 613-613.	1.4	0
348	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	1.4	0
349	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	1.4	0
350	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	1.4	0
351	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2862-2862.	1.4	0
352	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. Blood, 2010, 116, 4127-4127.	1.4	0
353	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. Blood, 2010, 116, 143-143.	1.4	1
354	Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Research, 2009, 69, 5522-5530.	0.9	140
355	Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 5404-5409.	1.6	259
356	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 2009, 113, 6669-6680.	1.4	297
357	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation. Blood, 2009, 113, 5206-5216.	1.4	46
358	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood, 2009, 114, 2936-2944.	1.4	144
359	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood, 2009, 114, 2926-2935.	1.4	152
360	A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma Blood, 2009, 114, 1665-1665.	1.4	6

#	Article	IF	CITATIONS
361	A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma Blood, 2009, 114, 1669-1669.	1.4	7
362	Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003) Blood, 2009, 114, 1676-1676.	1.4	7
363	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma Blood, 2009, 114, 2868-2868.	1.4	3
364	A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients Blood, 2009, 114, 3854-3854.	1.4	13
365	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma Blood, 2009, 114, 3884-3884.	1.4	0
366	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma Blood, 2009, 114, 1952-1952.	1.4	0
367	Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma Blood, 2009, 114, 2803-2803.	1.4	Ο
368	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma Blood, 2009, 114, 925-925.	1.4	1
369	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma Blood, 2009, 114, 3933-3933.	1.4	1
370	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia Blood, 2009, 114, 587-587.	1.4	2
371	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras Blood, 2009, 114, 443-443.	1.4	Ο
372	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma Blood, 2009, 114, 440-440.	1.4	4
373	Increased Immune Suppressive CD14+ hla-DRneg Circulating Monocytes Are Found in Aggressive Non-Hodgkin's Lymphoma and Correlated with Increased Arginase I Level Blood, 2009, 114, 970-970.	1.4	Ο
374	Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstrol îm Macroglobulinemia Blood, 2009, 114, 1691-1691.	1.4	1
375	Lowâ€dose, singleâ€agent temsirolimus for relapsed mantle cell lymphoma. Cancer, 2008, 113, 508-514.	4.1	220
376	Targeting NF-Î $^\circ$ B in Waldenstrom macroglobulinemia. Blood, 2008, 111, 5068-5077.	1.4	106
377	Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma Blood, 2008, 112, 2251-2251.	1.4	3
378	Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Blood, 2008, 112, 1763-1763.	1.4	1

#	Article	IF	CITATIONS
379	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 603-603.	1.4	4
380	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. Journal of Clinical Oncology, 2007, 25, 4285-4292.	1.6	142
381	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in in intratumoral CD4+CD25â^' T cells. Blood, 2007, 110, 2537-2544.	1.4	181
382	Standard Approaches to Relapsed Indolent Non-Hodgkin's Lymphoma. Seminars in Hematology, 2007, 44, S12-S17.	3.4	0
383	Serum-free light chain—a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Translational Research, 2007, 149, 231-235.	5.0	53
384	Longâ€ŧerm responses in patients with recurring or refractory Bâ€cell nonâ€Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 2007, 109, 1804-1810.	4.1	164
385	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL) Blood, 2007, 110, 121-121.	1.4	31
386	mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001) Blood, 2007, 110, 2555-2555.	1.4	14
387	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results Blood, 2007, 110, 4496-4496.	1.4	2
388	Role of CCL5 and Interleukin-6 in the Biology of WaldenstroÌ^m Macroglobulinemia Blood, 2007, 110, 688-688.	1.4	2
389	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21 Blood, 2007, 110, 3585-3585.	1.4	1
390	Absolute Lymphocyte Count Is Independent of the Anaplastic Lymphoma Kinase and Predicts Survival in Primary Anaplastic Large Cell Lymphoma Blood, 2007, 110, 1335-1335.	1.4	0
391	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study Blood, 2007, 110, 2615-2615.	1.4	0
392	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL) Blood, 2007, 110, 124-124.	1.4	2
393	Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL) Blood, 2007, 110, 1347-1347.	1.4	0
394	Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clinic Proceedings, 2007, 82, 692-9.	3.0	8
395	Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Practice and Research in Clinical Haematology, 2006, 19, 655-668.	1.7	36
396	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2006, 47, 629-636.	1.3	83

#	Article	IF	CITATIONS
397	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107, 3378-3383.	1.4	230
398	Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer, 2006, 107, 433-438.	4.1	19
399	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism Blood, 2006, 108, 234-234.	1.4	2
400	Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma Blood, 2006, 108, 2482-2482.	1.4	11
401	Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma Blood, 2006, 108, 2722-2722.	1.4	1
402	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274) Blood, 2006, 108, 530-530.	1.4	6
403	Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL) Blood, 2006, 108, 5125-5125.	1.4	0
404	Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas Blood, 2006, 108, 3878-3878.	1.4	0
405	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents Blood, 2006, 108, 3500-3500.	1.4	0
406	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution's Experience Blood, 2006, 108, 3062-3062.	1.4	0
407	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma Blood, 2006, 108, 817-817.	1.4	0
408	Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25â^' T Cells To Express Foxp3 and Gain Regulatory Function Blood, 2006, 108, 1724-1724.	1.4	17
409	Phenotypic Characterization of the CD45+ and CD45â^ Plasma Cell Compartments in Monoclonal Gammopathies Blood, 2006, 108, 3505-3505.	1.4	1
410	Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood, 2005, 105, 3722-3730.	1.4	136
411	Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy. Journal of Clinical Oncology, 2005, 23, 2606-2617.	1.6	199
412	Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology, 2005, 23, 1103-1108.	1.6	187
413	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	1.6	509
414	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines Blood, 2005, 106, 2411-2411.	1.4	3

#	Article	IF	CITATIONS
415	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma Blood, 2005, 106, 3475-3475.	1.4	6
416	Role of B-Lymphocyte Stimulator (BLyS) in Waldenstrom's Macroglobulinemia Blood, 2005, 106, 601-601.	1.4	7
417	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma Blood, 2005, 106, 781-781.	1.4	5
418	Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma Blood, 2005, 106, 931-931.	1.4	5
419	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy Blood, 2005, 106, 938-938.	1.4	8
420	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System Blood, 2005, 106, 1164-1164.	1.4	7
421	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12 Blood, 2005, 106, 1495-1495.	1.4	6
422	Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma Blood, 2005, 106, 3312-3312.	1.4	0
423	Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL Blood, 2005, 106, 3311-3311.	1.4	0
424	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma Blood, 2005, 106, 4698-4698.	1.4	0
425	Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin's Disease Blood, 2005, 106, 2667-2667.	1.4	0
426	Targeting Vla-4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti Vla-4 Therapy Blood, 2005, 106, 1182-1182.	1.4	0
427	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders Blood, 2005, 106, 2567-2567.	1.4	2
428	A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin's Lymphoma (NHL) Blood, 2005, 106, 4798-4798.	1.4	0
429	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood, 2004, 103, 4429-4431.	1.4	181
430	Waldenström macroglobulinemia. Current Treatment Options in Oncology, 2004, 5, 239-247.	3.0	49
431	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 478-481.	1.0	27
432	Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, 98-101.	2.1	117

#	Article	IF	CITATIONS
433	Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature. Clinical Lymphoma and Myeloma, 2004, 5, 202-204.	2.1	37
434	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group Blood, 2004, 104, 129-129.	1.4	6
435	Combination Therapy with CC-5013 (Lenalidomide; Revlimidâ"¢) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM) Blood, 2004, 104, 331-331.	1.4	16
436	Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs of Today, 2004, 40, 111.	2.4	32
437	Expression of Cytoplasmic and Surface VEGF by Plasma Cells in Myeloma and Related Disorders Blood, 2004, 104, 3655-3655.	1.4	3
438	Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway Blood, 2004, 104, 1909-1909.	1.4	4
439	The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy Blood, 2004, 104, 1296-1296.	1.4	0
440	Clinical and Biological Correlates of CD45 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma Blood, 2004, 104, 3362-3362.	1.4	0
441	APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma Blood, 2004, 104, 2652-2652.	1.4	0
442	PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells Blood, 2004, 104, 2478-2478.	1.4	0
443	Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms Blood, 2004, 104, 964-964.	1.4	0
444	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma Blood, 2004, 104, 1397-1397.	1.4	0
445	Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy Blood, 2004, 104, 2446-2446.	1.4	0
446	Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM) Blood, 2004, 104, 4299-4299.	1.4	0
447	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy Blood, 2004, 104, 787-787.	1.4	0
448	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience Blood, 2004, 104, 928-928.	1.4	0
449	Expression of VEGF Receptors on Plasma Cells: Evidence of Heterogeneity Blood, 2004, 104, 3361-3361.	1.4	4
450	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells Blood, 2004, 104, 2392-2392.	1.4	0

#	Article	IF	CITATIONS
451	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma Blood, 2004, 104, 2412-2412.	1.4	1
452	Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL) Blood, 2004, 104, 2629-2629.	1.4	0
453	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia Blood, 2004, 104, 2291-2291.	1.4	1
454	Efficacy and safety of 90Y ibritumomab tiuxetan (zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Seminars in Oncology, 2003, 30, 11-16.	2.2	37
455	Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2003, 21, 1263-1270.	1.6	278
456	Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Journal of Nuclear Medicine, 2003, 44, 465-74.	5.0	145
457	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 2002, 99, 4336-4342.	1.4	257
458	Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 3885-3890.	1.6	105
459	Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 2453-2463.	1.6	1,069
460	Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 3262-3269.	1.6	624
461	Heavy chain disease. Current Treatment Options in Oncology, 2002, 3, 247-254.	3.0	31
462	Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin's Lymphoma. Current Treatment Options in Oncology, 2002, 3, 275-282.	3.0	27
463	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-356.	1.0	16
464	Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clinical Cancer Research, 2002, 8, 1085-91.	7.0	126
465	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 2001, 68, 269-275.	4.1	61
466	Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 42, 1235-1241.	1.3	16
467	Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer, 2000, 88, 154-161.	4.1	147
468	Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology, 2000, 108, 737-742.	2.5	139

#	Article	IF	CITATIONS
469	Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 766-777.	6.4	210
470	Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20 ⁺ B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 1999, 17, 3793-3803.	1.6	525
471	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. Journal of Clinical Oncology, 1999, 17, 262-262.	1.6	77
472	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology, 1999, 17, 1551-1551.	1.6	64
473	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. Blood, 1999, 93, 1062-1066.	1.4	180
474	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. Leukemia and Lymphoma, 1999, 35, 599-605.	1.3	31
475	Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign. British Journal of Haematology, 1999, 107, 463-464.	2.5	12
476	Osseous Hodgkin disease. , 1999, 85, 1166-1178.		72
477	Thrombosis Related to the Use of L-Asparaginase in Adults with Acute Lymphoblastic Leukemia: a Need to Consider Coagulation Monitoring and Clotting Factor Replacement. Leukemia and Lymphoma, 1999, 32, 489-496.	1.3	28
478	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. British Journal of Haematology, 1998, 100, 326-327.	2.5	14
479	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. British Journal of Haematology, 1998, 101, 296-301.	2.5	70
480	Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1998, 31, 167-175.	1.3	62
481	Measurement of the Cell Proliferation Rate of Bone Marrow Erythroid Precursors by Flow Cytometry: Initial Applications to Multiple Myeloma. Leukemia and Lymphoma, 1998, 30, 353-359.	1.3	3
482	Heterogeneity and Clinical Relevance of the Intensity of CD20 and Immunoglobulin Light-Chain Expression in B-Cell Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 1996, 106, 457-461.	0.7	39
483	Detection of myeloma cells in the peripheral blood by flow cytometry. , 1996, 26, 113-120.		57
484	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. British Journal of Haematology, 1995, 90, 459-461.	2.5	30
485	Primary renal non-Hodgkin's lymphoma. An unusual extranodal site. Cancer, 1995, 75, 2258-2261.	4.1	121
486	S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer, 1995, 76, 1059-1064.	4.1	7

#	Article	IF	CITATIONS
487	Serial Studies of Peripheral Blood Myeloma Cells in Patients with Multiple Myeloma: When is the Optimal Time for Stem Cell Harvest?. Leukemia and Lymphoma, 1995, 19, 417-422.	1.3	8
488	Treatment of Refractory T-Cell Chronic Lymphocytic Leukemia with Purine Nucleoside Analogues. Leukemia and Lymphoma, 1994, 14, 137-139.	1.3	22
489	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 1994, 74, 2956-2963.	4.1	93
490	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. British Journal of Haematology, 1994, 87, 266-272.	2.5	89
491	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer, 1993, 72, 108-113.	4.1	71
492	Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer, 1993, 72, 1247-1260.	4.1	87
493	Consensus review of the clinical utility of dna flow cytometry in colorectal cancer. Cytometry, 1993, 14, 486-491.	1.8	111
494	Proliferative Activity in Non-Hodgkin's Lymphomas: <i>A Comparison of the Bromodeoxyuridine Labeling Index with PCNA Immunostaining and Quantitative Image Analysis</i> . American Journal of Clinical Pathology, 1993, 99, 668-672.	0.7	24
495	Is persistent polyclonal b lymphocytosis caused by epstein-barr virus? A study with polymerase chain reaction and in situ hybridization. American Journal of Hematology, 1992, 41, 270-275.	4.1	48
496	Unusual presentation of extranodal peripheral T-cell lymphomas with multiple paraneoplastic features. Cancer, 1991, 68, 834-841.	4.1	29
497	Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry. Cytometry, 1990, 11, 642-646.	1.8	38
498	Rapid S-Phase Determination of Non-Hodgkin's Lymphomas with the Use of an Immunofluorescence Bromodeoxyuridine Labeling Index Procedure. American Journal of Clinical Pathology, 1989, 91, 298-301.	0.7	13
499	Diagnosis of B-cell non-hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes. Cancer, 1986, 57, 737-744.	4.1	55
500	T-cell chronic lymphocytic leukemia with a helper/inducer membrane phenotype: A distinct clinicopathologic subtype with a poor prognosis. American Journal of Hematology, 1986, 21, 139-155.	4.1	22
501	Platelet transfusion therapy in acute leukemia: Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. American Journal of Hematology, 1985, 18, 345-350.	4.1	1
502	Protocol Modification To Determine The Cytotoxic Potential Of Drugs Using Cell Viability Assays That Rely On The Reducing Property Of Viable Cells. Protocol Exchange, 0, , .	0.3	3
503	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003–2018). American Journal of Hematology, 0, , .	4.1	4
504	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia and Lymphoma, 0, , 1-16.	1.3	1